8-K Announcements
6Material company update
Apr 30, 2026·SEC
Material company update
Apr 27, 2026·SEC
Material company update
Feb 20, 2026·SEC
Organon & Co.(OGN)Earnings, Financials & Key Ratios
OGN•NYSE
$13.50
18.8× P/E·Price updated Jun 27, 2026
AboutOrganon & Co., a health care company, develops and delivers health solutions through a portfolio of prescription therapies in the United States and internationally. Its women's health portfolio comprises contraception and fertility brands, such as Nexplanon/Implanon, a long-acting reversible contraceptive. The company's biosimilars portfolio consists of three immunology products, such as Brenzys, Renflexis, and Hadlima, as well as two oncology products, including Ontruzant and Aybintio. It also offers cardiovascular products, consisting of several cholesterol-modifying medicines under the Zetia, Ezetrol, Vytorin, Inegy, Rosuzet, and Zocor brands; Cozaar and Hyzaar for the treatment of hypertension; respiratory products for various treatments to control and prevent symptoms caused by asthma under the Singulair, Dulera, Zenhale, and Asmanex brand names; and Singulair, Nasonex, Clarinex, and Aerius for treating seasonal allergic rhinitis. In addition, the company provides dermatology products under the Diprosone and Elocon brand; bone health portfolio, including Fosamax brand name; non-opioid pain management products under the Arcoxia, Diprospan, and Celestone brand names; Proscar for the treatment of symptomatic benign prostatic hyperplasia; and Propecia for the treatment of male pattern hair loss. The company sells its products primarily to drug wholesalers and retailers, hospitals, and government agencies, as well as managed health care providers, such as health maintenance organizations, pharmacy benefit managers, and other institutions. Organon & Co. was incorporated in 2020 and is based in Jersey City, New Jersey.Show more
- Revenue$6.22B-2.9%
- EBITDA$1.64B-7.1%
- Net Income$187M-78.4%
- EPS (Diluted)0.72-78.4%
- Gross Margin54.09%-6.8%
- EBITDA Margin26.36%-4.3%
- Operating Margin20.67%-10.9%
- Net Margin3.01%-77.7%
- ROE30.56%-92.9%
OGN Price & Volume
Organon & Co. (OGN) stock price & volume — 10-year historical chart
Loading chart...
Persistent Revenue Contraction Challenges Capital Structure Stability
Investment Thesis • Updated 2026Q1
VerdictNegative
Growth:Decelerating
Profitability:Strained
Financial Position:Vulnerable
Cash Flow:Mixed
Primary Risk:High Debt Service Burden
"Organon faces a challenging fundamental outlook characterized by persistent revenue declines, with 2026Q1 sales falling 3.5% year-over-year, and significant margin compression as gross margins eroded to 53.6%. The company's reliance on a $8.6 billion debt load and a precarious equity base of $903 million creates substantial financial risk, particularly as capital allocation shifts toward acquisitions despite volatile cash flow generation. Investors should monitor the company's ability to stabilize its legacy portfolio and manage its high debt-to-EBITDA ratio of 24.41, which continues to constrain operational flexibility."
Verdict Logic
the company's high debt-to-EBITDA ratio of 24.41 and persistent revenue contraction suggest significant long-term solvency risks that outweigh the current 2.5% dividend yield.
OGN Growth Metrics
Organon & Co. (OGN) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years-
5 Years-0.99%
3 Years0.23%
TTM-2.08%
Profit CAGR
10 Years-
5 Years-38.7%
3 Years-41.14%
TTM-67.2%
EPS CAGR
10 Years-
5 Years-38.99%
3 Years-41.47%
TTM-67.71%
Return on Capital
10 Years24.35%
5 Years17.59%
3 Years14.21%
Last Year12.32%
OGN Recent Earnings
Organon & Co. (OGN) EPS & revenue vs analyst estimates — last 4 quarters
●Beat EPS 7/12 qtrs (58%)●Beat Revenue 6/12 qtrs (50%)
Q2 2026Latest
Apr 30, 2026Metric
Actual
Est
EPS
$0.71-14.5%
$0.83
Rev
$1.5B-1.9%
$1.5B
Q1 2026
Feb 12, 2026Metric
Actual
Est
EPS
$0.63-13.7%
$0.73
Rev
$1.5B-1.8%
$1.5B
Q4 2025
Nov 10, 2025Metric
Actual
Est
EPS
$1.01+8.6%
$0.93
Rev
$1.6B+5.3%
$1.5B
Q3 2025
Aug 5, 2025Metric
Actual
Est
EPS
$1.00+6.4%
$0.94
Rev
$1.6B+2.1%
$1.6B
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q2 2026Latest | Apr 30, 2026 | $0.71vs $0.83-14.5% | $1.5Bvs $1.5B-1.9% |
| Q1 2026 | Feb 12, 2026 | $0.63vs $0.73-13.7% | $1.5Bvs $1.5B-1.8% |
| Q4 2025 | Nov 10, 2025 | $1.01vs $0.93+8.6% | $1.6Bvs $1.5B+5.3% |
| Q3 2025 | Aug 5, 2025 | $1.00vs $0.94+6.4% | $1.6Bvs $1.6B+2.1% |
Based on last 12 quarters of dataView full earnings history →
Peers Comparison
Key metrics vs top competitors for Organon & Co. (OGN)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $13.50 | $3.55B | 18.75 | -2.92% | 3.01% | 30.56% | 2.5% | |
| $24.29 | $138.14B | 17.86 | -1.65% | 11.83% | 8.34% | — | |
| $16.33 | $19.02B | -5.44 | -2.98% | -2.04% | -1.97% | — | |
| $251.52 | $444.38B | 106.13 | 8.57% | 5.79% | 67.46% | — | |
| $9.24 | $41.15B | 19.43 | -3.96% | 14.46% | 19.9% | — | |
| $33.21 | $38.67B | 27.68 | 4.31% | 9.02% | 20.69% | — |
Compare OGN vs Peers
Organon & Co. (OGN) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
OGN SEC Filings & Documents
Organon & Co. (OGN) SEC filings — annual & quarterly reports (10-K, 10-Q)
Get notified when OGN posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
OGN Frequently Asked Questions
Organon & Co. (OGN) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
What is Organon & Co.'s revenue?
Organon & Co. (OGN) reported $6.16B in revenue for fiscal year 2025. This represents a 37% decrease from $9.78B in 2018.
How fast is Organon & Co. growing?
Organon & Co. (OGN) saw revenue decline by 2.9% over the past year.
Is OGN profitable?
Yes, Organon & Co. (OGN) is profitable, generating $246.0M in net income for fiscal year 2025 (3.0% net margin).
Dividend & Returns
Does OGN pay dividends?
Yes, Organon & Co. (OGN) pays a dividend with a yield of 2.50%. This makes it attractive for income-focused investors.
What is OGN's return on equity?
Organon & Co. (OGN) has a return on equity (ROE) of 30.6%. This is excellent, indicating efficient use of shareholder capital.
What is Organon & Co.'s free cash flow?
Organon & Co. (OGN) generated $614.0M in free cash flow for fiscal year 2025. Positive FCF indicates the company can fund dividends, buybacks, or reinvestment.